Prostamax vs MK-677 (Ibutamoren)
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
ProstamaxGrowth Hormone Peptides
MK-677 (Ibutamoren)- Summary
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- 24 hours
- Admin Route
- SubQ, Oral
- Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 10–25 mg
- Frequency
- Daily for 10–30 days
- Once daily
- Key Benefits
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Increases lean muscle mass
- Enhances bone density
- Improves sleep quality and REM sleep
- Accelerates recovery from training
- Increases appetite
- May improve skin elasticity and appearance
- Supports fat loss while maintaining muscle
- Oral administration — no injections required
- 24-hour half-life allows once-daily dosing
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Increased appetite (significant in some users)
- Water retention and puffiness
- Elevated blood glucose / insulin resistance (monitor in diabetics)
- Lethargy initially
- +2 more
- Stacks With
- —
- —